R&D News | pharmaphorum

News

Gilde’s new investment fund reaches €740m at close

Netherlands-based investment group Gilde Healthcare has finally closed its new Venture & Growth VI fund with committed funding of €740 million, well ahead of its origi

News

UK feels the chill of Pfizer’s cost-cutting wind

Pfizer has fleshed out some more of the details of its wide-ranging cost-cutting drive announced last month, revealing that around 500 jobs will go in the UK, including at

News

Autifony swings $770.5m deal with Jazz for CNS drugs

UK biotech Autifony has signed an exclusive licensing deal with Jazz Pharmaceuticals, giving the Ireland-headquartered drugmaker global rights to a pair of ion channel tar

News

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

AstraZeneca’s cancer immunotherapy Imfinzi broke new ground when it was approved in 2018 for locally advanced non-small cell lung cancer (NSCLC) that can’t be treated with

News

AHA: First data backs AskBio’s heart failure gene therapy

Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse event

News

AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year

A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein(a) – a risk factor for cardiovascular

Gilde’s new investment fund reaches €740m at close

UK feels the chill of Pfizer’s cost-cutting wind

Autifony swings $770.5m deal with Jazz for CNS drugs

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

AHA: First data backs AskBio’s heart failure gene therapy

AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks